SG194453A1 - Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset - Google Patents

Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset Download PDF

Info

Publication number
SG194453A1
SG194453A1 SG2013075668A SG2013075668A SG194453A1 SG 194453 A1 SG194453 A1 SG 194453A1 SG 2013075668 A SG2013075668 A SG 2013075668A SG 2013075668 A SG2013075668 A SG 2013075668A SG 194453 A1 SG194453 A1 SG 194453A1
Authority
SG
Singapore
Prior art keywords
treatment
cancer
motesanib
small cell
cell lung
Prior art date
Application number
SG2013075668A
Inventor
Yong-Jiang Hei
Bin Yao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG194453A1 publication Critical patent/SG194453A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a method of improving survival associated with cancer in a subset of the general population. The invention provides a method of improving survival associated with cancer in patients of Asian ethnic background. In addition, the present application relates to the treatment of angiogenesis related disease in an Asian patient with kinase inhibitors. In addition the present application relates to the treatment of non-small cell lung cancer in an Asian patient with motesanib.
SG2013075668A 2011-04-13 2012-04-12 Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset SG194453A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161475163P 2011-04-13 2011-04-13
PCT/US2012/033376 WO2012142325A1 (en) 2011-04-13 2012-04-12 Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset

Publications (1)

Publication Number Publication Date
SG194453A1 true SG194453A1 (en) 2013-12-30

Family

ID=46018098

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013075668A SG194453A1 (en) 2011-04-13 2012-04-12 Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset

Country Status (7)

Country Link
JP (1) JP2014510793A (en)
KR (1) KR20140022876A (en)
CN (1) CN103764139A (en)
AU (1) AU2012242773A1 (en)
SG (1) SG194453A1 (en)
TW (1) TW201304777A (en)
WO (1) WO2012142325A1 (en)

Also Published As

Publication number Publication date
CN103764139A (en) 2014-04-30
KR20140022876A (en) 2014-02-25
WO2012142325A1 (en) 2012-10-18
JP2014510793A (en) 2014-05-01
TW201304777A (en) 2013-02-01
AU2012242773A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
NZ602385A (en) Methods of treating cancer
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX2015008114A (en) Exendin-4 Derivatives.
PH12015500431A1 (en) Glucosylceramide synthase inhibitors
MX2019006379A (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy.
NZ716473A (en) Diagnosis and therapy of cancer involving cancer stem cells
MX2012007898A (en) Methods of providing weight loss therapy in patients with major depression.
MX2016011045A (en) Combination therapy for cancer.
NZ701553A (en) Medicine comprising combination of general anesthetic drug and hydrogen
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
WO2012082821A3 (en) Melanoma treatments
MX2015015601A (en) Method of treating lung cancer by vaccination with muc-1 lipopeptide.
BR112013019080A2 (en) methods for treating cancer, nsclc and colorectal cancer in a human patient and article of manufacture
PH12015502516A1 (en) Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment
SG194453A1 (en) Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset
EP2879712A4 (en) Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug
MX2012003287A (en) Use of the sparc microenvironment signature in the treatment of cancer.
SG10201908587PA (en) Treatment regimens
MX2015004940A (en) Treatment of depression and ptsd.
PH12014502464A1 (en) Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
UA73001U (en) method for treating patients with pulmonary tuberculosis combined with HIV/AIDS
UA78287U (en) Method for medical rehabilitation of patients with ischemic heart disease in setting of metabolic syndrome
UA84191U (en) Method for treating patients with non-alcoholic steatohepatitis in setting of diabetes mellitus type 2
UA67294U (en) method for prognostication of the COURSE of disease in patients with stomach cancer